Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (DE:MOL)
FRANKFURT:MOL
MOL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€6.45 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$13.05M
Enterprise Value€1.94M
Total Cash (Recent Filing)$7.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
May 08, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,302,494
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.31
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
€16.67Price Target Upside158.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Moleculin Biotech News
PremiumCompany Announcements
Moleculin Biotech Advances Clinical Trials Amid Financial Losses
PremiumCompany Announcements
Moleculin Biotech Shares Corporate Presentation Update---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnnamycin has shown no signs of cardiotoxicity and demonstrated efficacy in challenging acute myeloid leukemia settings, supporting a positive outlook despite valuation pullback.
Regulatory SupportRegulatory features of MIRACLE continue to support an accelerated timeline.
Treatment PotentialAnnamycin is differentiated from other anthracyclines for not showing cumulative cardiotoxicity, which limits long-term use of other anthracyclines.
Bears Say
Commercial TimelinesThe commercial timelines for Annamycin in acute myeloid leukemia have been pushed out to 2029 due to extended trial timelines.
Financial ConcernsThe company is seeking to raise capital through the sale of common stock and warrants, which could lead to significant share dilution and affect the company's ability to operate.
Stock Rating DowngradeThere is uncertainty about whether the company can raise enough capital to fund its projects, which has led to a downgrade in the stock rating.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.68% Insiders
0.39%
Mutual Funds
2.42% Other Institutional Investors
96.28% Public Companies and
Individual Investors
MOL FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $13.05M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 11, 2024. The company reported -€2.633 earnings per share for the quarter, missing the consensus estimate of -€2.254 by -€0.379.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -0.66.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 13,302,494 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -€2.633 in its last earnings report, missing expectations of -€2.254. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in DE:MOL
---
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
---
MOL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress and potential in the Phase III MIRACLE trial, strong efficacy in Phase II data, and the extended patent life of annamycin. However, challenges remain in recruitment, financial constraints, and the inherent risks of biotech trials.Read More>---
MOL Stock 12 Month Forecast
Average Price Target
€16.67
▲(158.37% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Medicinova
―
Immunic
―
Citius Pharmaceuticals
―
Atea Pharmaceuticals
―
Best Analysts Covering MOL
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-49.47%
assigned a buy rating 2 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -49.47% per trade.
---